AIkido Pharma Inc. [NASDAQ: AIKI] closed the trading session at $1.39 on 03/22/21. The day’s price range saw the stock hit a low of $1.31, while the highest price level was $1.42. The company report on March 12, 2021 that AIkido Pharma Announces Dr. Matt Frieman’s Appearance on This Week in Virology.
Dr. Frieman Discusses Development of Pan-Viral Drugs with AIkido.
AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) announced that Dr. Matt Frieman appeared on the video podcast This Week in Virology, segment entitled “TWiV 729: A floret of spikes with Matt Frieman.” In the video, Dr. Frieman discusses the Covid-19 pandemic from the point of view of a coronavirologist.
The stocks have a year to date performance of 59.13 percent and weekly performance of 2.21 percent. The stock has been moved at 135.19 percent over the last six months. The stock has performed -14.20 percent around the most recent 30 days and changed 101.51 percent over the most recent 3-months.
If compared to the average trading volume of 20.15M shares, AIKI reached to a volume of 17257274 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about AIkido Pharma Inc. [AIKI]:
The Average True Range (ATR) for AIkido Pharma Inc. is set at 0.20, with the Price to Sales ratio for AIKI stock in the period of the last 12 months amounting to 11628.12. The Price to Book ratio for the last quarter was 1.67, with the Price to Cash per share for the same quarter was set at 0.36.
AIKI stock trade performance evaluation
AIkido Pharma Inc. [AIKI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.21. With this latest performance, AIKI shares dropped by -14.20% in over the last four-week period, additionally plugging by 135.19% over the last 6 months – not to mention a rise of 142.25% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AIKI stock in for the last two-week period is set at 53.53, with the RSI for the last a single of trading hit 57.39, and the three-weeks RSI is set at 52.72 for AIkido Pharma Inc. [AIKI]. The present Moving Average for the last 50 days of trading for this stock 1.3772, while it was recorded at 1.3160 for the last single week of trading, and 0.8873 for the last 200 days.
AIkido Pharma Inc. [AIKI]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AIkido Pharma Inc. [AIKI] shares currently have an operating margin of -63166.67. AIkido Pharma Inc.’s Net Margin is presently recorded at -46477.78.
Return on Total Capital for AIKI is now -50.24, given the latest momentum, and Return on Invested Capital for the company is -36.97. Return on Equity for this stock declined to -36.97, with Return on Assets sitting at -34.10.
Reflecting on the efficiency of the workforce at the company, AIkido Pharma Inc. [AIKI] managed to generate an average of -$1,394,333 per employee.AIkido Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 59.60 and a Current Ratio set at 59.60.
AIkido Pharma Inc. [AIKI]: Insider Ownership positions
There are presently around $1 million, or 3.20% of AIKI stock, in the hands of institutional investors. The top three institutional holders of AIKI stocks are: VANGUARD GROUP INC with ownership of 144,440, which is approximately 41% of the company’s market cap and around 5.62% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 138,246 shares of the stock with an approximate value of $0.19 million in AIKI stocks shares; and VIRTU FINANCIAL LLC, currently with $0.12 million in AIKI stock with ownership of nearly New of the company’s market capitalization.
Positions in AIkido Pharma Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 11 institutional holders increased their position in AIkido Pharma Inc. [NASDAQ:AIKI] by around 318,618 shares. Additionally, 10 investors decreased positions by around 258,618 shares, while 2 investors held positions by with 36,708 shares. The mentioned changes placed institutional holdings at 613,944 shares, according to the latest SEC report filing. AIKI stock had 6 new institutional investments in for a total of 211,632 shares, while 7 institutional investors sold positions of 159,135 shares during the same period.